A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

Published:2012-08 Issue:8 Volume:23 Page:2094-2102
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Doebele R.C.,Conkling P.,Traynor A.M.,Otterson G.A.,Zhao Y.,Wind S.,Stopfer P.,Kaiser R.,Camidge D.R.

Funder

Eli Lilly & Co.

ImClone Systems

Novartis

Bayer

Pfizer

Genentech

Abraxis

Tragara

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/8/2094/13787810/mdr596.pdf

Reference22 articles.

1. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

2. Salvage therapy in patients with advanced non-small cell lung cancer;Bedano;J Thorac Oncol,2006

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

5. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer;Akerley;J Clin Oncol,2008

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer;JNCI Cancer Spectrum;2024-04-30

2. Current status and future of anti-angiogenic drugs in lung cancer;Clinical and Experimental Medicine;2023-03-15

3. Transition Metal-Decorated B₁₂N₁₂–X (X = Au, Cu, Ni, Os, Pt, and Zn) Nanoclusters as Biosensors for Carboplatin;ACS Omega;2023-03-07

4. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review;Frontiers in Immunology;2023-01-10

5. Polypharmacology in Clinical Applications—Anticancer Polypharmacology;Polypharmacology;2022